Joachim Ögren1, Anna-Lotta Irewall2, Lisa Bergström2, Thomas Mooe2. 1. From the Department of Public Health and Clinical Medicine, Unit of Research, Education and Development - Östersund, Umeå University, Umeå, Sweden. Joachim.ogren@regionjh.se. 2. From the Department of Public Health and Clinical Medicine, Unit of Research, Education and Development - Östersund, Umeå University, Umeå, Sweden.
Abstract
BACKGROUND: Epidemiological data on the risk of intracranial hemorrhage (ICrH) after ischemic stroke are sparse. The aims of this study were to describe incidence, trends over time, and predictors of ICrH within 1 year after ischemic stroke. METHODS AND RESULTS: All patients registered in the Swedish stroke register Riksstroke for 1998 to 2009 were included (n=196 765), and data were combined with the National Patient Register to identify ICrH occurrence. A matched reference population was obtained. Incidence rates and cumulative incidences were calculated. Multivariable regression analyses were used to identify predictors. Analyses were performed separately for the first 30 days and days 31 to 365 after ischemic stroke. The incidence rate was 1.97% per year at risk for the first year (0.13% in the reference population) and 0.85% excluding the first 30 days. Over time, the cumulative incidence increased the first 30 days but decreased over days 31 to 365. Thrombolysis, previous ICrH, atrial fibrillation, and male sex were associated with increased risk of ICrH during the first 30 days. Previous ICrH, increasing age, and male sex were associated with increased risk during days 31 to 365. Statins and antithrombotic treatment did not independently predict ICrH occurrence. CONCLUSIONS: The incidence of ICrH within 1 year after ischemic stroke was ≈2% per year at risk, about 15 times higher compared with the reference population. Over the study period, ICrH risk increased within the first 30 days but decreased thereafter. Previous ICrH, thrombolysis, and male sex affected the risk, whereas an increased use of antithrombotic treatments and statins did not.
BACKGROUND: Epidemiological data on the risk of intracranial hemorrhage (ICrH) after ischemic stroke are sparse. The aims of this study were to describe incidence, trends over time, and predictors of ICrH within 1 year after ischemic stroke. METHODS AND RESULTS: All patients registered in the Swedish stroke register Riksstroke for 1998 to 2009 were included (n=196 765), and data were combined with the National Patient Register to identify ICrH occurrence. A matched reference population was obtained. Incidence rates and cumulative incidences were calculated. Multivariable regression analyses were used to identify predictors. Analyses were performed separately for the first 30 days and days 31 to 365 after ischemic stroke. The incidence rate was 1.97% per year at risk for the first year (0.13% in the reference population) and 0.85% excluding the first 30 days. Over time, the cumulative incidence increased the first 30 days but decreased over days 31 to 365. Thrombolysis, previous ICrH, atrial fibrillation, and male sex were associated with increased risk of ICrH during the first 30 days. Previous ICrH, increasing age, and male sex were associated with increased risk during days 31 to 365. Statins and antithrombotic treatment did not independently predict ICrH occurrence. CONCLUSIONS: The incidence of ICrH within 1 year after ischemic stroke was ≈2% per year at risk, about 15 times higher compared with the reference population. Over the study period, ICrH risk increased within the first 30 days but decreased thereafter. Previous ICrH, thrombolysis, and male sex affected the risk, whereas an increased use of antithrombotic treatments and statins did not.
Authors: Alvin S Das; Elif Gökçal; Robert W Regenhardt; Andrew D Warren; Alessandro Biffi; Joshua N Goldstein; W Taylor Kimberly; Anand Viswanathan; Lee H Schwamm; Jonathan Rosand; Steven M Greenberg; M Edip Gurol Journal: J Neurol Date: 2022-08-23 Impact factor: 6.682
Authors: Alexandros A Polymeris; Annaelle Zietz; Fabian Schaub; Louisa Meya; Christopher Traenka; Sebastian Thilemann; Benjamin Wagner; Lisa Hert; Valerian L Altersberger; David J Seiffge; Flurina Lyrer; Tolga Dittrich; Ines Piot; Josefin Kaufmann; Lea Barone; Ludvig Dahlheim; Sophie Flammer; Nikolaos S Avramiotis; Nils Peters; Gian Marco De Marchis; Leo H Bonati; Henrik Gensicke; Stefan T Engelter; Philippe A Lyrer Journal: Eur Stroke J Date: 2022-05-10
Authors: Antonio Muscari; Luca Faccioli; Maria Vittoria Lega; Andrea Lorusso; Marco Masetti; Marco Pastore Trossello; Giovanni M Puddu; Luca Spinardi; Marco Zoli Journal: Brain Behav Date: 2019-12-17 Impact factor: 2.708
Authors: Sara Bernardo-Castro; João André Sousa; Ana Brás; Carla Cecília; Bruno Rodrigues; Luciano Almendra; Cristina Machado; Gustavo Santo; Fernando Silva; Lino Ferreira; Isabel Santana; João Sargento-Freitas Journal: Front Neurol Date: 2020-12-09 Impact factor: 4.003
Authors: Konstantin N Yarygin; Daria D Namestnikova; Kirill K Sukhinich; Ilya L Gubskiy; Alexander G Majouga; Irina V Kholodenko Journal: Cells Date: 2021-11-03 Impact factor: 6.600
Authors: Alexandros A Polymeris; Kosmas Macha; Maurizio Paciaroni; Duncan Wilson; Masatoshi Koga; Manuel Cappellari; Sabine Schaedelin; Annaelle Zietz; Nils Peters; David J Seiffge; David Haupenthal; Luise Gassmann; Gian Marco De Marchis; Ruihao Wang; Henrik Gensicke; Svenja Stoll; Sebastian Thilemann; Nikolaos S Avramiotis; Bruno Bonetti; Georgios Tsivgoulis; Gareth Ambler; Andrea Alberti; Sohei Yoshimura; Martin M Brown; Masayuki Shiozawa; Gregory Y H Lip; Michele Venti; Monica Acciarresi; Kanta Tanaka; Maria Giulia Mosconi; Masahito Takagi; Rolf H Jäger; Keith Muir; Manabu Inoue; Stefan Schwab; Leo H Bonati; Philippe A Lyrer; Kazunori Toyoda; Valeria Caso; David J Werring; Bernd Kallmünzer; Stefan T Engelter Journal: Ann Neurol Date: 2021-11-29 Impact factor: 11.274